 Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that new translational data for BT5528 and preclinical data for tumor-targeted immune cell agonists TICAsTM will be presented during poster sessions at the American Association for Cancer Research AACR Virtual Annual Meeting II on June 22-24, 2020. 